Literature DB >> 22556405

Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT.

Y K Kim1, G Park, C S Kim, H C Yu, Y M Han.   

Abstract

OBJECTIVES: We compared the diagnostic performance of gadoxetic acid-enhanced MRI and 16-slice multidetector CT (MDCT) with respect to their abilities to detect hepatic metastases and differentiate hepatic metastases from hepatic cysts and haemangiomas.
METHODS: 67 patients with 110 liver metastases (size 0.3-2.5 cm), 33 haemangiomas (size 0.5-1.5 cm) and 17 cysts (size 0.3-1.0 cm) underwent 4-phase MDCT and gadoxetic acid-enhanced MRI, including early dynamic phases, post-contrast T(2) weighted turbo spin echo sequences and 20 min hepatocyte-selective phases. Two observers independently analysed each image in random order. Sensitivity and diagnostic accuracy for lesion detection and differentiation for MDCT and gadoxetic acid-enhanced MRI were calculated using receiver operating characteristic analysis.
RESULTS: For both observers, the Az values of gadoxetic acid-enhanced MRI (mean, 0.982 and 0.981) were significantly higher than the Az values of MDCT (mean, 0.839 and 0.892) (p<0.05) for the detection of metastases and for the differentiation of metastases from haemangiomas and cysts. Sensitivities of gadoxetic acid-enhanced MRI with regard to the detection and characterisation of liver metastases (mean, 96.9% and 96.0%) were significantly higher than those of MDCT (mean, 78.7% and 75.0%) (p<0.05).
CONCLUSION: Gadoxetic acid-enhanced MRI showed higher diagnostic accuracy and sensitivity than did MDCT for the detection of hepatic metastases and for the differentiation between hepatic metastases and hepatic haemangiomas or cysts.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22556405      PMCID: PMC3479888          DOI: 10.1259/bjr/25139667

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  29 in total

1.  Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine.

Authors:  G Park; Y K Kim; C S Kim; H C Yu; S B Hwang
Journal:  Br J Radiol       Date:  2010-08-03       Impact factor: 3.039

2.  Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial.

Authors:  Juha Halavaara; Josy Breuer; Carmen Ayuso; Thomas Balzer; Marie-France Bellin; Lennart Blomqvist; Rick Carter; Luigi Grazioli; Renate Hammerstingl; Alexander Huppertz; Gregor Jung; Denis Krause; Andrea Laghi; Edward Leen; Luciano Lupatelli; Luca Marsili; Julio Martin; E Scott Pretorius; Caroline Reinhold; Michael Stiskal; Alan H Stolpen
Journal:  J Comput Assist Tomogr       Date:  2006 May-Jun       Impact factor: 1.826

3.  Detection and characterization of liver metastases: 16-slice multidetector computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging.

Authors:  Young Kon Kim; Seog Wan Ko; Seung Bae Hwang; Chong Soo Kim; Hee Chul Yu
Journal:  Eur Radiol       Date:  2006-02-02       Impact factor: 5.315

4.  Detection of liver metastases: Gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran-enhanced MR imaging.

Authors:  Young Kon Kim; Young Hwan Lee; Hyo Sung Kwak; Chong Soo Kim; Young Min Han
Journal:  Eur J Radiol       Date:  2008-11-08       Impact factor: 3.528

5.  Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT.

Authors:  Carlo Bartolozzi; Francescamaria Donati; Dania Cioni; Carlo Procacci; Giovanni Morana; Antonio Chiesa; Luigi Grazioli; Giorgio Cittadini; Giuseppe Cittadini; Andrea Giovagnoni; Giovanni Gandini; Jochen Maass; Riccardo Lencioni
Journal:  Eur Radiol       Date:  2003-08-09       Impact factor: 5.315

Review 6.  Management of colorectal liver metastases.

Authors:  G Fusai; B R Davidson
Journal:  Colorectal Dis       Date:  2003-01       Impact factor: 3.788

7.  Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach".

Authors:  Tito Livraghi; Luigi Solbiati; Franca Meloni; Tiziana Ierace; S Nahum Goldberg; G Scott Gazelle
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

8.  Multi-detector row helical CT in preoperative assessment of small (< or = 1.5 cm) liver metastases: is thinner collimation better?

Authors:  Masoom A Haider; Marianne M Amitai; Daniel C Rappaport; Martin E O'Malley; Anthony E Hanbidge; Mark Redston; Gina A Lockwood; Steven Gallinger
Journal:  Radiology       Date:  2002-10       Impact factor: 11.105

9.  Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions.

Authors:  Young Kon Kim; Jeong Min Lee; Chong Soo Kim
Journal:  Eur Radiol       Date:  2003-11-05       Impact factor: 5.315

10.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings.

Authors:  Alexander Huppertz; Thomas Balzer; Anthony Blakeborough; Josy Breuer; Andrea Giovagnoni; Gertraud Heinz-Peer; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Mueller; Peter Reimer; Philip J Robinson; Michael Strotzer; Matthias Taupitz; Thomas J Vogl
Journal:  Radiology       Date:  2004-01       Impact factor: 11.105

View more
  13 in total

Review 1.  "Vanishing liver metastases"-A real challenge for liver surgeons.

Authors:  Alex Zendel; Eylon Lahat; Yael Dreznik; Barak Bar Zakai; Rony Eshkenazy; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography.

Authors:  Cindy Chew; Patrick J O'Dwyer
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

3.  Does Gadoxetic acid-enhanced 3.0T MRI in addition to 64-detector-row contrast-enhanced CT provide better diagnostic performance and change the therapeutic strategy for the preoperative evaluation of colorectal liver metastases?

Authors:  Keitaro Sofue; Masakatsu Tsurusaki; Takamichi Murakami; Shunsuke Onoe; Hiroyuki Tokue; Kentaro Shibamoto; Yasuaki Arai; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

4.  Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases.

Authors:  Nobuyuki Asato; Masakatsu Tsurusaki; Keitaro Sofue; Yoko Hieda; Takashi Katsube; Kazuhiro Kitajima; Takamichi Murakami
Journal:  Jpn J Radiol       Date:  2017-03-01       Impact factor: 2.374

Review 5.  Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis.

Authors:  Thomas D Vreugdenburg; Ning Ma; Joanna K Duncan; Dagmara Riitano; Alun L Cameron; Guy J Maddern
Journal:  Int J Colorectal Dis       Date:  2016-09-29       Impact factor: 2.571

6.  A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases.

Authors:  Valérie Vilgrain; Maxime Esvan; Maxime Ronot; Aurore Caumont-Prim; Christophe Aubé; Gilles Chatellier
Journal:  Eur Radiol       Date:  2016-02-16       Impact factor: 5.315

7.  The imaging viewpoint: how imaging affects determination of progression-free survival.

Authors:  Daniel Carl Sullivan; Lawrence H Schwartz; Binsheng Zhao
Journal:  Clin Cancer Res       Date:  2013-05-15       Impact factor: 12.531

8.  Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation.

Authors:  M Scharitzer; A Ba-Ssalamah; H Ringl; C Kölblinger; T Grünberger; M Weber; W Schima
Journal:  Eur Radiol       Date:  2013-03-22       Impact factor: 5.315

Review 9.  Liver-specific agents for contrast-enhanced MRI: role in oncological imaging.

Authors:  Yee Liang Thian; Angela M Riddell; Dow-Mu Koh
Journal:  Cancer Imaging       Date:  2013-12-30       Impact factor: 3.909

10.  Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions.

Authors:  Michael Haimerl; Max Wächtler; Ivan Platzek; Rene Müller-Wille; Christoph Niessen; Patrick Hoffstetter; Andreas Georg Schreyer; Christian Stroszczynski; Philipp Wiggermann
Journal:  BMC Med Imaging       Date:  2013-12-01       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.